TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01167413

Intervention type: DEVICE
Intervention: Evaluation by manual Dolorimeter
Description: Patients will be examined by a manual Dolorimeter

Intervention type: OTHER
Intervention: SIJ imaging
Description: Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
Study: NCT02445898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Sodium Chloride
Description: Placebo
Study: NCT00645996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (L.acidophilus and B.lactis)
Description: 2.1 X 109 L.acidophilus and B.lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cornflor
Description: Cornflour 2 gram daily
Study: NCT02145377

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 10E8
Description: Oral dose of PXVX0200 10E8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 10E8
Description: Oral dose of PXVX0200 10E8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 10E9
Description: Oral dose of PXVX0200 10E9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PXVX0200 10E9
Description: Oral dose of PXVX0200 10E9

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose of sodium bicarbonate buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose of sodium bicarbonate buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose of sodium bicarbonate buffer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose of sodium bicarbonate buffer

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Shanchol
Description: Licensed comparator
Study: NCT00905801

Intervention type: OTHER
Group type: OTHER
Intervention: CT Perfusion
Description: Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).

Intervention type: OTHER
Group type: OTHER
Intervention: CT Perfusion
Description: Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
Study: NCT02067481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
Study: NCT01941186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
Study: NCT02386540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
Study: NCT02670096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
Study: NCT01915589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refametinib (BAY86-9766)
Description: All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
Study: NCT02560558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
Study: NCT02245217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scan to assess treatment efficacy
Study: NCT04926389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low-level laser therapy applied on days 0, 3,7,14 & every 2 weeks
Description: one side of the maxillary arch will randomly receive LLLT on days 0, 3, 7, 14, and every 2 weeks thereafter and the contralateral side will serve as the controls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-level laser therapy applied every 3 weeks
Description: one side will also be randomly chosen to receive LLLT every 3 weeks and the contralateral side will serve as the controls.
Study: NCT04366817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological assessment
Description: psychological assessment at D10-12 and 6-8 weeks : Scheduled telephone interview using the assessment scales (EPDS, PPQ, MIBS, DAS-16) on D10-D12 and 6-8 weeks postpartum with a psychologist
Study: NCT03849508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Drug: Phenylephrine variable infusion with a starting rate of 0,5μg/kg/min~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg
Study: NCT02999672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg qw via IV infusion) or Regimen B (3.6 mg/kg q3w via IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
Study: NCT03854097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Intermittent Negative Pressure (INP)
Description: Application of -40mmHg negative pressure on the lower limb

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Intermittent Negative Pressure (INP)
Description: Application of -40mmHg negative pressure on the lower limb

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intermittent Negative Pressure (INP)
Description: Application of -10mmHg negative pressure on the lower limb
Study: NCT00787358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZT-031
Description: 80 ul subcutaneous injection per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 80 ul daily subcutaneous injection of vehicle only
Study: NCT04640220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular steroid injection
Description: Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection
Study: NCT03470298

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratching
Description: The patients in study undergo endometrial scratch technique after being randomly assigned in to one of two groups . First group undergo oocyte pickup just after finishing oocyte pick up and the other group undergo oocyte pickup one week before starting COH.ManualVaccum Aspiration (MVA) size 5 moved from below upwards with suction ,scrachning anterior uterine wall then posterior then left lateral uterine wall then right lateral uterine wall and lastly fundus. All patients were prescribed vibramycine 100 mg twice daily for 3 days starting one day before procedure
Study: NCT00132704

Intervention type: RADIATION
Intervention: Ionizing radiation (IR) therapy
Description: Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.

Intervention type: RADIATION
Intervention: Ionizing radiation (IR)
Description: Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
Study: NCT03562377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tdap vaccine
Description: Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Description: Tetanus (lockjaw), diphtheria (infection of the nose and throat), and pertussis (whooping cough) vaccine. All subjects will receive 1 dose at Week 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Meningococcal vaccine
Description: This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine
Description: This vaccine is used to prevent meningococcal diseases (infection of the brain and spinal cord) and blood poisoning. All subjects will receive 1 dose at Week 12.
Study: NCT04495920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGB-S-100
Description: Alcohol and choline geranate
Study: NCT02633709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part 1 of the study matching oral placebo will be administered once on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Single ascending oral doses of Risdiplam will be administered on Day 1 of Part 1. In Part 2 a single dose of Risdiplam will be once administered under fasted and once under fed conditions. In Part 3 a single dose of Risdiplam will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
Study: NCT03135964

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filler dressing of NPWT
Description: a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: filler dressing of NPWT
Description: a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
Study: NCT02542319

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mablet 360 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01775618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 EDs and a minimum of at least 6 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Twice per week prophylaxis: 25-60 IU/kg, intravenous infusion, for 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAY94-9027
Description: Study drug dosing was adjusted to the clinical needs of each subject in the range of 25-60 IU/kg/administration, intravenous infusion, at least 50 additional EDs to achieve at least 100 cumulative EDs, or until marketing authorization of the drug
Study: NCT05109143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository
Description: 100mg Indomethacin Suppository administered at the time of Induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT01684813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel.
Description: Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
Study: NCT03171571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching procedure
Description: In this study, the volunteers will be followed during one year. The wellbeing will be followed with :~* survey like FFQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers
Study: NCT04182828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: both the drugs will be prepared in same volume, color, consistency and appearance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: both the drugs will be prepared in same volume, color, consistency and appearance
Study: NCT00515762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: elasto-gel cap
Description: scalp cooling cap
Study: NCT02280408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline placebo.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V920
Description: Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^6, 2x10\^7, or 1x10\^8 pfu.
Study: NCT03248206

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle changes
Description: Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle changes
Description: Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
Study: NCT00526071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study: NCT05242627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Firearm Safety Counseling Module
Description: The DGSOM class of 2024 will participate in a mandatory 1-hour module covering four main domains: (1) firearm epidemiology; (2) suicide epidemiology and introduction to means matter; (3) firearm counseling; and (4) an example of standardized patient encounter that includes a discussion of firearm safety with the patient. The module will be taught in combination by the study team, subject matter experts, and the DGSOM Standardized Patient Program.
Study: NCT02743104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Study: NCT01680471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03mg/kg
Description: This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05mg/kg
Description: This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.